← Leaderboards
John J Kopchick
Ohio University Athens
$6,608,823
Attributed
$7,189,696
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2007–25$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,189,696 · 6
By mechanism
R01$4,101,713 · 1
P01$1,635,790 · 1
R41$497,664 · 1
R21$415,250 · 1
R25$318,779 · 1
R15$220,500 · 1
Top collaborators
- Richard S Brody2 shared
- Derek Major Huffman2 shared
- Sofiya Milman2 shared
- Justin Matthew Holub1 shared
Most similar at Ohio University Athens
Same institution · by research overlap
- Justin Matthew Holub$207,625
Others in their field
Top investigators on “Molecular”
- David Heimbrook · Leidos Biomedical Research, Inc.$871,088,761
- Leonard Freedman · Leidos Biomedical Research, Inc.$468,573,385
- Richard Webby · St. Jude Children'S Research Hospital$254,843,170
- Larry Arthur$238,531,074
- Gregory H Reaman · National Childhood Cancer Foundation$230,630,913
- Ralph Parchment · Leidos Biomedical Research, Inc.$193,231,914
Research focus
MolecularDiabetes MellitusLongevityAgingGrowth Hormone ReceptorInsulin-Like Growth Factor IInsulin SensitivityLaboratoriesLifeInnovationPhysiologicalSomatotropinPathway InteractionsFutureInsulinTissuesDesignProductionLiverPhenotypeAcromegalyGeneticFemaleMetabolic
Grant awards (20)
Combining GHR antagonism with life extending compounds: a search for synergies$613,541
R01 · FY2025 · AG · contact PI
Development of a Growth Hormone Receptor antagonist for the delay or prevention of ADRD$222,594
R41 · FY2025 · AG
Diabetes Institute Summer Interprofessional Research Experience (DISIRE) for Undergraduates$104,496
R25 · FY2025 · DK · contact PI
Combining GHR antagonism with life extending compounds: a search for synergies$625,013
R01 · FY2024 · AG · contact PI
Development of a Growth Hormone Receptor antagonist for the delay or prevention of ADRD$275,070
R41 · FY2024 · AG
Diabetes Institute Summer Interprofessional Research Experience (DISIRE) for Undergraduates$106,283
R25 · FY2024 · DK · contact PI
Combining GHR antagonism with life extending compounds: a search for synergies$628,088
R01 · FY2023 · AG · contact PI
Developing helical peptide antagonists of the growth hormone receptor$415,250
R21 · FY2023 · AG
Modulating Growth Hormone Action as a Target for Improved Health and Longevity$414,111
R01 · FY2022 · AG · contact PI
Diabetes Institute Summer Interprofessional Research Experience (DISIRE) for Undergraduates$108,000
R25 · FY2022 · DK · contact PI
Modulating Growth Hormone Action as a Target for Improved Health and Longevity$436,385
R01 · FY2021 · AG · contact PI
Modulating Growth Hormone Action as a Target for Improved Health and Longevity$448,944
R01 · FY2020 · AG · contact PI
Modulating Growth Hormone Action as a Target for Improved Health and Longevity$466,068
R01 · FY2019 · AG · contact PI
Modulating Growth Hormone Action as a Target for Improved Health and Longevity$469,563
R01 · FY2018 · AG · contact PI
GENERATION OF TISSUE-SPECIFIC KNOCKOUT MICE$303,957
P01 · FY2013 · AG · contact PI
GENERATION OF TISSUE-SPECIFIC KNOCKOUT MICE$334,432
P01 · FY2012 · AG · contact PI
GENERATION OF TISSUE-SPECIFIC KNOCKOUT MICE$345,632
P01 · FY2011 · AG · contact PI
GENERATION OF TISSUE-SPECIFIC KNOCKOUT MICE$332,672
P01 · FY2010 · AG · contact PI
GENERATION OF TISSUE-SPECIFIC KNOCKOUT MICE$319,097
P01 · FY2009 · AG · contact PI
Creation and characterization of GH binding protein gene disrupted mice$220,500
R15 · FY2007 · DK · contact PI